RxDoctor Payments Data

Rajeev Garg, MD

Cardiovascular Disease · Phoenix, AZNPI 1275624231

Payments from drug & device makers

$21,640in general payments, 2019–2025

Across 581 payments — averaging $37.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Boston Scientific$2K
  • Abiomed$1K
  • Novartis$1K
  • Edwards Lifesciences$972
  • Merck$835
  • plus $7K from 45 others

What the payments were for

  • Consulting fees$3,15015%
  • Travel & lodging$2,18710%
  • Food & beverage$16,15375%
  • Education$1511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,640 in reported general payments places this provider in the 80th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$762,654
Medicare patients
946
Services billed
7,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban377$484,301
FarxigaDapagliflozin Propanediol127$118,710
JardianceEmpagliflozin87$103,676
EntrestoSacubitril/Valsartan45$73,633
XareltoRivaroxaban36$42,570
Repatha SureclickEvolocumab27$33,738
Metoprolol Succinate478$6,726
BrilintaTicagrelor12$6,004
VascepaIcosapent Ethyl12$5,976
Losartan Potassium523$5,430
Ezetimibe153$4,156
Atorvastatin Calcium453$4,153
ClopidogrelClopidogrel Bisulfate256$3,237
Flecainide Acetate35$2,229
Ranolazine ErRanolazine16$2,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$478$484,301377 claims
AstraZenecaFarxiga, Brilinta$628$124,714139 claims
Boehringer IngelheimJardiance$489$103,67687 claims
NovartisEntresto$1,356$73,63345 claims
Johnson & JohnsonXarelto$639$42,57036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →